Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: Finlabo SIM Spa
Provider: Reuters Investment Profile
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG's Stivarga Approved For Further Indication In Japan-Reuters

Tuesday, 20 Aug 2013 03:12am EDT 

Reuters reported that Bayer AG said it received regulatory approval in Japan for the marketing of cancer treatment Stivarga for patients with gastrointestinal stromal tumours who have progressed after prior systemic cancer therapy. Stivarga is already approved in several countries, including the United States and Japan, for the treatment of patients with metastatic colorectal cancer (mCRC). It was recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with mCRC in June 2013, with a decision by the European Commission on the marketing authorisation later in 2013. 

Company Quote

-0.2 -0.16%
3 Jun 2015